| Literature DB >> 34044011 |
Walhan Alshaer1, Hadil Zureigat2, Arwa Al Karaki2, Abdulfattah Al-Kadash2, Lobna Gharaibeh3, Ma'mon M Hatmal4, Alaa A A Aljabali5, Abdalla Awidi6.
Abstract
Owing to specific and compelling gene silencing, RNA interference (RNAi) is expected to become an essential approach in treating a variety of infectious, hemato-oncological, cardiovascular, and neurodegenerative conditions. The mechanism of action of small interfering RNA (siRNA) is based on post-transcriptional gene silencing. siRNA molecules are usually specific and efficient in the knockdown of disease-related genes. However, they are characterized by low cellular uptake and are susceptible to nuclease-mediated degradation. Therefore, siRNAs require a carrier for their protection and efficient delivery into target cells. The current review highlights the siRNA-based mechanism of action, challanges, and recent advances in clinical applications.Entities:
Keywords: Delivery systems; Gene knockdown; Nanocarriers; Nucleic acids-based therapeutics; siRNA
Mesh:
Substances:
Year: 2021 PMID: 34044011 DOI: 10.1016/j.ejphar.2021.174178
Source DB: PubMed Journal: Eur J Pharmacol ISSN: 0014-2999 Impact factor: 4.432